Abiopharma

🔍 Shackley Brian Charles (Executive)

Company: AeroVironment Inc (AVAV)

Report Date: 2026-06-29

Detailed Transactions and Holdings:

• Acquired 2,382 shares of Common Stock (Direct)
  Date: 2026-06-29 | Code: M | equity_swap_involved: 0 | shares_owned_after: 8,883.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 855 shares of Common Stock at $139.0 per share (Direct)
  Date: 2026-06-29 | Code: F | equity_swap_involved: 0 | shares_owned_after: 8,028.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 953 shares of Performance Restricted Stock Awards (Derivative)
  Date: 2026-06-29 | Code: M | Expires: 2026-06-29 | Exercise: 2026-06-29 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F3, F3, F4

Footnotes:

• F1: Each Performance Restricted Stock Unit (PRSU) represents the contingent right to receive, following vesting, shares of the issuer's common stock. The resulting number of shares of the issuer's common stock acquired upon vesting of the PRSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, over a three-year performance period beginning on May 1, 2023 and ending on April 30, 2026. The target number of units subject to the award is presented in the table. The number of units that vest may be 0% to 250% of the target number of units, depending on performance.
• F2: Disposition made pursuant to a net settlement whereby shares of stock were tendered to satisfy tax withholding obligations arising in the conjunction with the vesting of previously issued Performance Restricted Stock Units.
• F3: Unless earlier forfeited under the terms of the PRSU, each PRSU vests and converts into shares of the issuer's common stock upon certification by the Company's Compensation Committee of the achievement of the performance metrics of the PRSUs (the "Certification Date").
• F4: Upon conversion of the PRSUs, the Reporting Person received 2,382 shares of common stock.